{"id":17126,"date":"2015-11-02T11:08:40","date_gmt":"2015-11-02T10:08:40","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=17126"},"modified":"2015-11-02T11:08:40","modified_gmt":"2015-11-02T10:08:40","slug":"incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/","title":{"rendered":"Incumplimiento terap\u00e9utico del paciente con EPOC: \u00bfqu\u00e9 hacemos mal?"},"content":{"rendered":"<p><b>Las enfermedades respiratorias representan en torno al 6% del gasto sanitario y m\u00e1s de la mitad de \u00e9ste es atribuible a la enfermedad pulmonar obstructiva cr\u00f3nica (EPOC). Se calcula que el 9,1% de la poblaci\u00f3n entre 40 y 80 a\u00f1os sufre esta enfermedad<\/b> y uno de cada cinco contactos hospitalarios por patolog\u00eda respiratoria en Catalu\u00f1a es por EPOC. En el tratamiento de esta enfermedad la v\u00eda inhalada es la elecci\u00f3n, pero los sistemas de inhalaci\u00f3n s\u00f3lo son efectivos si se utilizan correctamente. Sin embargo, debe tenerse en cuenta que no todos son apropiados por todos los pacientes porque en la selecci\u00f3n del dispositivo deben considerarse las comorbilidades, la polimedicaci\u00f3n, la habilidad, el estado cognitivo, la aptitud y las preferencias del paciente y \/o cuidadores (enfermos con deterioro cognitivo).<\/p>\n<p style=\"text-align: center;\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/10\/jornada-MPOC-octubre-global.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-17129 aligncenter\" alt=\"jornada-MPOC-octubre-global\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/10\/jornada-MPOC-octubre-global.jpg\" width=\"610\" height=\"228\" \/><\/a><\/p>\n<figure id=\"attachment_17133\" aria-describedby=\"caption-attachment-17133\" style=\"width: 268px\" class=\"wp-caption alignright\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/10\/jornada-MPOC-octubre-webinar.jpg\"><img decoding=\"async\" class=\"wp-image-17133\" alt=\"jornada-MPOC-octubre-webinar\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/10\/jornada-MPOC-octubre-webinar.jpg\" width=\"268\" height=\"179\" \/><\/a><figcaption id=\"caption-attachment-17133\" class=\"wp-caption-text\">La sesi\u00f3n se pudo seguir por Webinar (retransmitido en tiempo real por medio de internet)<\/figcaption><\/figure>\n<p><b>La adherencia y el cumplimiento terap\u00e9utico del tratamiento pueden verse favorecidos por la simplificaci\u00f3n del tratamiento y del sistema de inhalaci\u00f3n<\/b>. La educaci\u00f3n y la instrucci\u00f3n en los pacientes son factores clave para obtener los efectos \u00f3ptimos. Los profesionales de la salud deben conocer los diferentes tratamientos y dispositivos disponibles y es por este motivo que se organiz\u00f3 el curso \u201cIncumplimiento terap\u00e9utico del paciente con EPOC: \u00bfqu\u00e9 hacemos mal?\u201d, que acogi\u00f3 el COFB el 8 de octubre , en la que se quiso dar una visi\u00f3n global del estado actual del tratamiento y manejo del paciente con EPOC, incidiendo sobre todo en la terapia inhalatoria.<\/p>\n<p><b>Joan Juvanteny<\/b>, m\u00e9dico de familia y de atenci\u00f3n comunitaria, director EAP Via Barcino (ICS) y miembro del grupo de enfermedades del aparato respiratorio de la CAMFiC, describi\u00f3 el abordaje farmacol\u00f3gico de esta patolog\u00eda, explicando cu\u00e1l es la estrategia actual a la hora de seleccionar los tratamientos seg\u00fan las caracter\u00edsticas del paciente y el grado de evoluci\u00f3n de la enfermedad. Sin embargo, dej\u00f3 patente que una vez seleccionado el f\u00e1rmaco o f\u00e1rmacos tambi\u00e9n es importante tener en cuenta el dispositivo inhalatorio.<\/p>\n<p>En este aspecto <b>Jordi Giner<\/b>, enfermero del Departamento de Neumolog\u00eda del Hospital de la Santa Cruz y San Pablo, mostr\u00f3 que no s\u00f3lo es el paciente el que puede tener problemas al saber c\u00f3mo utilizar este dispositivo sino que hay estudios que han observado una desconocimiento importante para parte de los profesionales sanitarios (farmac\u00e9uticos, m\u00e9dicos y enfermeras) de c\u00f3mo son y c\u00f3mo se utilizan estos dispositivos.<\/p>\n\n<p>Finalmente <b>Esther Amado,<\/b> farmac\u00e9utica de atenci\u00f3n primaria, referente del \u00c1rea del Medicamento y Servicio de Farmacia del \u00c1mbito de Atenci\u00f3n Primaria Barcelona Ciutat (Institut Catal\u00e0 de la Salut) y <b>Merc\u00e8 Barau<\/b>, vocal del Colegio, farmac\u00e9utica comunitaria y responsable del grupo de trabajo de atenci\u00f3n farmac\u00e9utica del COFB y una de las coordinadoras de la formaci\u00f3n, explicaron c\u00f3mo los farmac\u00e9uticos pueden contribuir en el correcto seguimiento y manejo de estos pacientes.<\/p>\n<p>En el caso de la atenci\u00f3n primaria, el farmac\u00e9utico ayuda a dar a conocer que nos dice la evidencia cient\u00edfica sobre el tratamiento de la EPOC, y c\u00f3mo trasladar a la pr\u00e1ctica cl\u00ednica diaria estos conocimientos con criterios de calidad y seguridad. Por lo que respecta a la farmacia comunitaria, el farmac\u00e9utico contribuye en la detecci\u00f3n de problemas en el manejo de la medicaci\u00f3n por parte del paciente y participa en programas de salud que contribuyen en la mejora del manejo del paciente con EPOC, como por ejemplo en la deshabituaci\u00f3n tab\u00e1quica o en programas de cribado.<\/p>\n<figure id=\"attachment_17134\" aria-describedby=\"caption-attachment-17134\" style=\"width: 264px\" class=\"wp-caption alignright\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/10\/jornada-MPOC-roser-valles.jpg\"><img decoding=\"async\" class=\"wp-image-17134\" alt=\"jornada-MPOC-roser-valles\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/10\/jornada-MPOC-roser-valles.jpg\" width=\"264\" height=\"222\" \/><\/a><figcaption id=\"caption-attachment-17134\" class=\"wp-caption-text\">Roser Vall\u00e8s, farmac\u00e9utica<\/figcaption><\/figure>\n<p><div class=\"box shadow\">Tras las exposiciones individuales hubo un espacio de debate entre los ponentes y los asistentes donde se discutieron temas relacionados con la terapia de la EPOC y el rol que puede jugar cada profesional, m\u00e9dico, enfermera y farmac\u00e9uticos de los distintos niveles asistenciales. <b>Roser Vall\u00e8s, vocal de Atenci\u00f3n Primaria del COFB, y una de las coordinadoras de esta formaci\u00f3n junto a Merc\u00e8 Barau<\/b>, resume las principales conclusiones que suscit\u00f3 este debate con los puntos claves expuestos en la jornada:<\/p>\n<ul>\n<li>Se echa de menos una comunicaci\u00f3n y una relaci\u00f3n m\u00e1s cercana entre los profesionales de atenci\u00f3n primaria y la farmacia comunitaria.<\/li>\n<li>Por eso faltan todav\u00eda desarrollar circuitos de coordinaci\u00f3n y canales de comunicaci\u00f3n establecidos entre oficina de farmacia y atenci\u00f3n primaria.<\/li>\n<li>Es necesario aplicar criterios de calidad en el seguimiento y evaluaci\u00f3n de la actividad asistencial de la oficina de farmacia y tambi\u00e9n potenciar m\u00e1s su aplicaci\u00f3n en los dem\u00e1s colectivos para incentivar la formaci\u00f3n y mejorar las competencias profesionales.<\/li>\n<li>En definitiva, es fundamental la acreditaci\u00f3n y la evaluaci\u00f3n de las competencias profesionales de cada colectivo (farmac\u00e9utico, m\u00e9dico y enfermero) porque los profesionales bien formados y cualificados son los que pueden ayudar mejor a los pacientes en el manejo de sus patolog\u00edas y tratamientos.<\/div><\/li>\n<\/ul>\n<p align=\"right\"><b>Con la colaboraci\u00f3n de:<\/b><\/p>\n<p align=\"right\"><a href=\"http:\/\/www.astrazeneca.es\/inicio\/\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-6822 alignright\" alt=\"astrazeneca_logo\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2014\/06\/astrazeneca_logo.jpg\" width=\"150\" height=\"36\" \/><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Las enfermedades respiratorias representan en torno al 6% del gasto sanitario y m\u00e1s de la mitad de \u00e9ste es atribuible a la enfermedad pulmonar obstructiva cr\u00f3nica (EPOC). Se calcula que el 9,1% de la poblaci\u00f3n entre 40 y 80 a\u00f1os padece esta enfermedad y uno de cada cinco contactos hospitalarios [\u2026]<\/p>","protected":false},"author":1,"featured_media":17254,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[2187,64,938,53,2274,226,1004],"class_list":["post-17126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-adherencia","tag-atencio-farmaceutica","tag-atencio-primaria","tag-farmaceutics","tag-inhalacio","tag-malalties-respiratories","tag-mpoc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Incompliment terap\u00e8utic del pacient amb MPOC: qu\u00e8 fem malament? - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Incompliment terap\u00e8utic del pacient amb MPOC: qu\u00e8 fem malament? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Les malalties respirat\u00f2ries representen al voltant del 6% de la despesa sanit\u00e0ria i m\u00e9s de la meitat d&#8217;aquesta \u00e9s atribu\u00efble a la malaltia pulmonar obstructiva cr\u00f2nica (MPOC). Es calcula que el 9,1% de la poblaci\u00f3 entre 40 i 80 anys pateix aquesta malaltia i un de cada cinc contactes hospitalaris [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-11-02T10:08:40+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Incompliment terap\u00e8utic del pacient amb MPOC: qu\u00e8 fem malament?\",\"datePublished\":\"2015-11-02T10:08:40+00:00\",\"dateModified\":\"2015-11-02T10:08:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/\"},\"wordCount\":890,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"adher\u00e8ncia\",\"Atenci\u00f3 farmac\u00e8utica\",\"Atenci\u00f3 prim\u00e0ria\",\"farmac\u00e8utics\",\"inhalaci\u00f3\",\"malalties respirat\u00f2ries\",\"MPOC\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/\",\"name\":\"Incompliment terap\u00e8utic del pacient amb MPOC: qu\u00e8 fem malament? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2015-11-02T10:08:40+00:00\",\"dateModified\":\"2015-11-02T10:08:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Incompliment terap\u00e8utic del pacient amb MPOC: qu\u00e8 fem malament?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Incompliment terap\u00e8utic del pacient amb MPOC: qu\u00e8 fem malament? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/","og_locale":"es_ES","og_type":"article","og_title":"Incompliment terap\u00e8utic del pacient amb MPOC: qu\u00e8 fem malament? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Les malalties respirat\u00f2ries representen al voltant del 6% de la despesa sanit\u00e0ria i m\u00e9s de la meitat d&#8217;aquesta \u00e9s atribu\u00efble a la malaltia pulmonar obstructiva cr\u00f2nica (MPOC). Es calcula que el 9,1% de la poblaci\u00f3 entre 40 i 80 anys pateix aquesta malaltia i un de cada cinc contactes hospitalaris [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2015-11-02T10:08:40+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Incompliment terap\u00e8utic del pacient amb MPOC: qu\u00e8 fem malament?","datePublished":"2015-11-02T10:08:40+00:00","dateModified":"2015-11-02T10:08:40+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/"},"wordCount":890,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#primaryimage"},"thumbnailUrl":"","keywords":["adher\u00e8ncia","Atenci\u00f3 farmac\u00e8utica","Atenci\u00f3 prim\u00e0ria","farmac\u00e8utics","inhalaci\u00f3","malalties respirat\u00f2ries","MPOC"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/","url":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/","name":"Incompliment terap\u00e8utic del pacient amb MPOC: qu\u00e8 fem malament? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#primaryimage"},"thumbnailUrl":"","datePublished":"2015-11-02T10:08:40+00:00","dateModified":"2015-11-02T10:08:40+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2015\/11\/02\/incompliment-terapeutic-del-pacient-amb-mpoc-que-fem-malament\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Incompliment terap\u00e8utic del pacient amb MPOC: qu\u00e8 fem malament?"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"Les malalties respirat\u00f2ries representen al voltant del 6% de la despesa sanit\u00e0ria i m\u00e9s de la meitat d&#8217;aquesta \u00e9s atribu\u00efble a la malaltia pulmonar obstructiva cr\u00f2nica (MPOC). Es calcula que el 9,1% de la poblaci\u00f3 entre 40 i 80 anys pateix aquesta malaltia i un de cada cinc contactes hospitalaris [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/17126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=17126"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/17126\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=17126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=17126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=17126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}